Concord Wealth Partners Buys 140 Shares of IQVIA Holdings Inc. $IQV

Concord Wealth Partners raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 60.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 373 shares of the medical research company’s stock after acquiring an additional 140 shares during the quarter. Concord Wealth Partners’ holdings in IQVIA were worth $59,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the period. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA in the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH bought a new position in IQVIA in the second quarter valued at approximately $39,000. Finally, Larson Financial Group LLC increased its stake in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 144 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on IQV shares. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $195.00 to $235.00 in a research note on Thursday. UBS Group lifted their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, Robert W. Baird raised their target price on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $234.57.

IQVIA Price Performance

Shares of NYSE:IQV opened at $203.95 on Tuesday. The firm has a market cap of $34.67 billion, a PE ratio of 29.52, a price-to-earnings-growth ratio of 2.18 and a beta of 1.32. The firm’s fifty day moving average is $189.44 and its 200-day moving average is $168.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.